Galectin Therapeutics
在场
Galectin Therapeutics 是一家在股票代码 GALT (US) 下上市的公司。
高管
查看带有其 20 名主要高管的组织结构图
Galectin Therapeutics 搜索最多的简介
- Joel Lewis, President, Chief Executive Officer and Director
- Kary Eldred, Director
- Richard Uihlein, Chairman of the Board
高管在Galectin Therapeutics变化
- Khurram Jamil已作为Vice President, Clinical Development加入公司 (新闻发布的2024三月13号).
- Benjamin Carson已作为Director加入公司 (新闻发布的2023十月12号).
创建提醒
跟踪 Galectin Therapeutics 的高管变动
生物技术
Galectin Therapeutics 拥有 2,276 家竞争者，其中包括 Eurofins (卢森堡)、Lonza (瑞士) 和 Adaptive Phage Therapeutics (美国(美洲))。
Popular M&A news in 生物技术
- Histogen has filed for bankruptcy protection (公布2024四月19号).
- Bruker has announced the acquisition of NanoString Technologies (公布2024四月18号).
- Vertex Pharmaceuticals has announced the acquisition of Alpine Immune Sciences (公布2024四月16号).
生物技术 行业的其他推荐联系人
消息
Galectin Therapeutics 的最新新闻稿
- Galectin Therapeutics Announces $60 Million Credit Line from Richard E. Uihlein Sufficient to Cover Expected Expenditures Through 2024 | Galectin Therapeutics Inc.
- Galectin Therapeutics Announces 2 Liver Cirrhosis Scientific Presentations at the EASL International Liver Congress™ 2022 | Galectin Therapeutics Inc.
- Galectin Therapeutics to Present in Upcoming H.C. Wainwright Global Investment Conference and the 5th Global NASH Congress | Galectin Therapeutics Inc.
- Galectin Therapeutics Investor Conference Call and Webinar Taking Place Today | Galectin Therapeutics Inc.
- Galectin Therapeutics Announces Investor Conference Call and Webinar on September 29, 2020 | Galectin Therapeutics Inc.
- Galectin Therapeutics Inc. to Present at the H.C. Wainwright 22nd Annual Global Investment Conference on September 14, 2020 | Galectin Therapeutics Inc.
- Galectin Therapeutics Appoints Joel Lewis as Chief Executive Officer | Galectin Therapeutics Inc.
- Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2020, and Provides Business Update | Galectin Therapeutics Inc.
- Galectin Therapeutics Announces Commencement of Patient Enrollment of the Adaptively-Designed Phase 2b/3 Trial of Belapectin in NASH Cirrhosis | Galectin Therapeutics Inc.
- UPDATE -- Galectin Therapeutics Announces Commencement of Patient Enrollment of the Adaptively-Designed Phase 2b/3 Trial of Belapectin in NASH Cirrhosis | Galectin Therapeutics Inc.
- View more press releases Close
通过电子邮件
